Ashutosh Wechalekar

In this insightful discussion, Vaishali Sanchorawala, a leading expert in amyloidosis from Boston University, and Ashutosh Wechalekar, a prominent hematologist from University College London, delve into the cutting-edge findings presented at the recent ASH meeting. They highlight breakthrough results from the ANDROMEDA trial, emphasizing the effectiveness of daratumumab VCD for AL amyloidosis treatment. The duo also explores advancements in risk stratification and the promising role of measurable residual disease and CAR T-cell therapy in enhancing patient care.

Experts Shaji Kumar and Ashutosh Wechalekar discuss highlights from the ISA 2022 meeting, including diagnostic approaches in AL amyloidosis, advances in imaging techniques, and the role of stem cell transplantation in the era of daratumumab-based therapies.